Framingham pharma firm to test hemophilia drug
rEVO Biologics of Framingham will begin late-stage trials of a drug intended to prevent and treat hemophilia A and B bleeding episodes in patients who have developed resistance to other treatments.
The initial Phase III study will evaluate two LR769 dosing regiments for the treatment of bleeding, with results expected in the second half of this year, said rEVO, a subsidiary of Europe-based LFB SA.
Subsequent studies, slated for early 2015, will evaluate the effectiveness of LR769 in treating bleeding episodes in pediatric hemophilia patients with inhibitors, as well as preventing bleeding complications in patients undergoing surgery.
“If proven safe and effective, LR769 would provide doctors will the first new therapeutic option in more than 15 years for these difficult-to-treat hemophilia patients,” said Christian Bechon, LFB chairman and CEO.
Approximately 15 to 20 percent of hemophilia patients develop resistance to products used to treat bleeding episodes, according to the Centers for Disease Control and Prevention.
(Image credit: freedigitalphotos.net)
WBJ Web Partners
Most Recent
Most Recent
0 Comments